Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.

ABSTRACT:

Background

Treated secondary acute myeloid leukemia (ts-AML)-i.e., AML arising from a previously treated antecedent hematologic disorder-is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertain.

Methods

We retrospectively analyzed 562 patients who developed AML from preceding myelodysplastic syndrome or chronic myelomonocytic leukemia for which they had received a hypomethylating agent (HMA). Patients with ts-AML were stratified by frontline AML treatment with intensive chemotherapy (IC, n = 271), low-intensity therapy (LIT) without venetoclax (n = 237), or HMA plus venetoclax (n = 54).

Results

Compared with IC or LIT without venetoclax, HMA plus venetoclax resulted in higher CR/CRi rates (39% and 25%, respectively

SUBMITTER: Short NJ 

PROVIDER: S-EPMC8800349 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature